Working… Menu

US Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00515164
Recruitment Status : Completed
First Posted : August 13, 2007
Last Update Posted : October 24, 2011
Information provided by (Responsible Party):
Aeris Therapeutics

Brief Summary:
The purpose of this study it to evaluate the efficacy and safety of the 20 mL BLVR System in patients with advanced upper lobe predominant emphysema.

Condition or disease Intervention/treatment Phase
Pulmonary Emphysema Chronic Obstructive Pulmonary Disease Drug: Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel Phase 2

Detailed Description:


Patients with emphysema currently have limited treatment choices. Many patients are treated with steroids and inhaled medications, which often provide little or no benefit. In recent years, lung volume reduction surgery has become an accepted therapy for advanced emphysema. Lung volume reduction surgery involves the removal of diseased portions of the lung in order to enable the remaining, healthier portions of the lung to function better. This procedure, although effective for many patients, is complicated and is accompanied by substantial morbidity and mortality risk.

Aeris Therapeutics has developed the Biologic Lung Volume Reduction (BLVR) System which is intended to achieve lung volume reduction without surgery and its attendant risks. Patients are treated using a bronchoscope to direct treatment to the most damaged areas of the lung. The treatment delivers a precisely proportioned proprietary mixture of drugs and biologics which, when combined at the treatment site, form a biodegradable hydrogel. The hydrogel acts to reduce lung volume by permanently collapsing and sealing the diseased areas of the lung. This provides room within the chest to allow the remaining healthier portions of the lung to function better.

Aeris' BLVR development program has been granted Fast Track designation by the U.S. FDA, and is the subject of ongoing clinical trials designed to investigate the safety and efficacy of the BLVR System as a treatment for patients with advanced heterogeneous emphysema. Fast Track designation is reserved for drug and biologic development programs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Study of the 20 mL Biologic Lung Volume Reduction System (BLVR) in Patients With Advanced Upper Lobe Predominant Emphysema
Study Start Date : August 2007
Actual Primary Completion Date : April 2008
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Emphysema

Arm Intervention/treatment
Experimental: Group 1
Treatment will be administered in 2 treatment sessions.
Drug: Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel
20 mL Hydrogel

Experimental: Group 2
Treatment will be administered in a single treatment session.
Drug: Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel
20 mL Hydrogel

Primary Outcome Measures :
  1. Reduction in gas trapping [ Time Frame: 12 weeks post treatment ]
  2. SAEs - Safety of treatment and the procedure [ Time Frame: 2 years post treatment ]

Secondary Outcome Measures :
  1. Improvement in exercise capacity [ Time Frame: 12 weeks post treatment ]
  2. Improvement in vital capacity [ Time Frame: 12 weeks post treatment ]
  3. Improvement in expiratory flow [ Time Frame: 12 weeks post treatment ]
  4. Improvement in inspiratory flow [ Time Frame: 12 weeks post treatment ]
  5. Improvement in dyspnea symptoms (breathlessness) [ Time Frame: 12 weeks post treatment ]
  6. Improvement in respiratory quality of life [ Time Frame: 12 weeks post treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • clinical diagnosis of advanced upper lobe emphysema
  • age >/= 40 years
  • clinically significant dyspnea
  • failure of standard medical therapy to relieve symptoms (inhaled beta agonist & inhaled anticholinergic)
  • pulmonary function tests within protocol-specified ranges (post bronchodilator FEV1 < 45% predicted & experiencing < 30% or 300 mL improvement using bronchodilator; total lung capacity > 110% predicted; residual volume > 150% predicted)
  • 6 Minute Walk Distance >/= 150 m

Exclusion Criteria:

  • alpha-1 protease inhibitor deficiency
  • homogeneous emphysema
  • tobacco use within 4 months of initial visit
  • body mass index < 15 kg/m2 or> 35 kg/m2
  • clinically significant asthma, chronic bronchitis or bronchiectasis
  • allergy or sensitivity to procedural components
  • pregnant, lactating or unwilling to use birth control if required
  • prior lung volume reduction surgery, lobectomy, pneumonectomy, lung transplant, endotracheal valve placement, airway stent placement or pleurodesis
  • comorbid condition that could adversely influence outcomes
  • inability to tolerate bronchoscopy under conscious sedation (or anesthesia)
  • history of renal infarction or renal failure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00515164

Layout table for location information
United States, Arizona
Pulmonary Associates
Phoenix, Arizona, United States, 85006
United States, Iowa
University of Iowa Hospitals & Clinics
Iowa City, Iowa, United States, 52242
United States, Kansas
Veritas Clinical Specialties, Ltd
Topeka, Kansas, United States, 66606
United States, Maryland
St Joseph's Medical Center
Towson, Maryland, United States, 21204
United States, Ohio
Akron Medical Center
Akron, Ohio, United States, 44302
Pulmonary, Allergy & Critical Care Medicine, Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
Temple University Lung Center
Philadelphia, Pennsylvania, United States, 19140
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
Sponsors and Collaborators
Aeris Therapeutics
Layout table for investigator information
Principal Investigator: Geoffrey McLennan, MD University of Iowa Hospitals & Clinics, Iowa City, IA
Principal Investigator: Charlie Strange, MD Medical University of South Carolina
Principal Investigator: Mark Gotfried, MD Pulmonary Associates, Phoenix, AZ
Principal Investigator: Mark Krasna, MD St Joseph's Medical Center, Towson, MD
Principal Investigator: Sanjiv Tewari, MD Akron Medical Center, Akron, OH
Principal Investigator: Gerard Criner, MD Temple University Lung Center, Philadelphia, PA
Principal Investigator: William Leeds, DO Veritas Clinical Specialties, Topeka, KS
Principal Investigator: Thomas Gildea, MD Pulmonary, Allergy & Critical Care Medicine, Cleveland Clinic, Cleveland, OH
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Aeris Therapeutics Identifier: NCT00515164    
Other Study ID Numbers: 01-C07-001
First Posted: August 13, 2007    Key Record Dates
Last Update Posted: October 24, 2011
Last Verified: October 2011
Keywords provided by Aeris Therapeutics:
lung volume reduction
chronic obstructive pulmonary disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Pulmonary Emphysema
Respiratory Tract Diseases
Pathologic Processes